Hydralazine 25 mg Tablets

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

1. What Hydralazine 25 mg Tablets are and what they are used for
2. What you need to know before you take Hydralazine 25 mg Tablets
3. How to take Hydralazine 25 mg Tablets
4. Possible side effects
5. How to store Hydralazine 25 mg Tablets
6. Contents of the pack and other information

• if you are allergic to hydralazine or any of the other ingredients in this medicine (listed in section 6) (allergic reactions include mild symptoms such as itching and/or rash. More severe symptoms include swelling of the face, lips, tongue and/or throat with difficulty in swallowing or breathing);
• if you have or have ever had a condition called Systemic Lupus Erythematosus (SLE), an autoimmune condition which causes joint pain, skin rashes and fever;
• if you suffer from severe tachycardia or right sided heart failure due to increased pressure in the blood vessels of the lungs (cor pulmonale);
• if you suffer from thyrotoxicosis (an excess of thyroid hormones in the blood that can cause a fast heartbeat, sweating, trembling, anxiety, increased appetite, loss of weight and intolerance of heat);
• if you heart function impaired (myocardial insufficiency);
• if you have a condition known as porphyria.

Talk to your doctor or pharmacist before taking Hydralazine 25 mg tablets

• if you have had a heart attack in the past three months;
• if you have angina pectoris, which causes pain in the chest with exercise;
• if you have cerebrovascular disease (narrowing of the blood vessels in the brain);
• if you have been told you are a slow acetylator (this means that your body handles some medicines more slowly than other people);
• if you suffer from any serious liver or kidney problems;
• if you have blockage of one or more arteries that supply blood to the heart (coronary heart disease).

Hydralazine 25 mg Tablets are not recommended for use in children.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

It is especially important that you tell your doctor if you are taking:

• medicines for high blood pressure, such as vasodilators (e.g. minoxidil or diazoxide);
• ACE inhibitors (e.g. enalapril, lisinopril, captopril);
• beta-blockers (e.g. propranolol);
• calcium antagonists (e.g. nifedipine or diltiazem);
• medicines for water retention (e.g. diuretics);
• medicines for problems such as depression, including monoamine oxidase inhibitors (MAOIs)(e.g. moclobemide, phenelzine, isocarboxazid, tranylcypromine);
• tricyclic antidepressants (e.g amitriptyline, clomipramine) or tranquillisers (e.g. diazepam);
• medicines to control pain and inflammation (a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs));
• medicines to control psychoses;
• a specific group of medicines known as nitrates, used to control blood pressure;
• oestrogens (a group of female sex hormones used in contraception and in treating the menopause).

If you are going to have a general anaesthetic, you should tell the doctor or dentist in charge that you are taking Hydralazine 25 mg Tablets.

It is advisable not to drink alcohol whilst taking hydralazine as it may affect you more than usual.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

You can drive while taking hydralazine but do not drive until you know how the tablets affect you. They may make you feel dizzy or impair your reactions. If they affect you in this way, do not drive or operate any machinery.

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

High blood pressure: The usual starting dose is one tablet (25 mg) taken twice a day. This may be increased up to 8 tablets a day (maximum of 200mg) by your doctor.

Heart failure: Treatment should be started in hospital, at a dose of 25 mg three or four times a day. 50 mg to 75mg four times a day is often given as a long-term dose. Your doctor will adjust the dose to suit you.

Hydralazine 25 mg Tablets is not recommended for use in children.

The tablets should be taken with a drink of water.

Ask your doctor before stopping treatment with hydralazine, as treatment should be stopped gradually over several days.

If you take more Hydralazine 25 mg Tablets than you should, contact your doctor or go to your nearest hospital emergency department immediately. Take the container and any remaining tablets with you.

If you forget to take a dose, just take the next dose at the usual time, DO NOT take a double dose to make up for a forgotten dose.

Very common (may affect more than 1 in 10 people)

• abnormal heartbeat (palpitations);
• an unusually fast heartbeat;
• headaches.

Common (may affect up to 1 in 10 people)

• chest pains;
• swelling and/or pain in joints, muscle pain;
• low blood pressure;
• feeling sick and being sick, particularly at the beginning of the treatment or after an increase in dose;
• diarrhoea;
• flushing.

Rare (may affect up to 1 in 1,000 people)

• heart failure, swelling;
• increased levels of a substance called creatinine in the blood;
• breathlessness, breathing difficulties or pain when breathing;
• liver enlargement;
• skin rash;
• blood in the urine which may be associated with a disease of the kidneys;
• presence of protein in the urine;
• inflammation or the abnormal functioning of the liver;
• watering or sore itchy eyes (conjunctivitis);
• a reduction in the number of platelets in the blood which can cause unexplained bruising or rashes;
• a reduction in red blood cells, which can make you feel tired or breathless with physical exertion;
• a reduction in certain white blood cells which may make you more susceptible to infections;
• fever;
• anxiety;
• restlessness;
• blocked or stuffy nose;
• loss of appetite;
• weight loss;
• dizziness;
• generally feeling unwell.

Isolated cases

• a change in the amount of urine produced;
• a restriction of movement in part of the intestine;
• a deficiency of certain white blood cells which can result in fever and ulceration of the mouth and throat;
• an increased number of white blood cells;
• enlargement of the spleen;
• a reduction in the number of red and white blood cells and platelets in the blood;
• depression;
• seeing or hearing things which are not really there (hallucinations);
• inflammation of the nerves which may cause weakness or numbness especially in your fingers and toes;
• tingling (pins and needles) in your hands or feet;
• disease of the lymph nodes;
• enlarged eye balls;
• the inability to completely or partially empty the bladder;
• opposite effect of medical treatment (episodes of high blood pressure);
• an increase in other kinds of white blood cells.

If you feel very tired, experience unexpected bruising or bleeding, or more infections (e.g. colds and sore throats) than usual please tell your doctor. Your doctor may decide to conduct tests on your blood periodically as a result of these symptoms.

If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

The active substance is hydralazine hydrochloride. The other ingredients are: silicon dioxide, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, maize starch, hydroxypropylmethylcellulose, povidone, talc, titanium dioxide (E171), polyethylene glycol, sucrose, yellow iron oxide, shellac glaze, black iron oxide (E172), red iron oxide (E172), ammonium hydroxide(E527), propylene glycol(E1520) and water.

Hydralazine 25 mg Tablets are pale yellow, round, biconvex sugar-coated tablets.

Hydralazine 25 mg Tablets are available in packs of 56, 84 or 100 tablets.

Not all pack sizes may be marketed.